Literature DB >> 1924360

Involvement of wild-type p53 in pre-B-cell differentiation in vitro.

G Shaulsky1, N Goldfinger, A Peled, V Rotter.   

Abstract

Wild-type p53 protein is a growth modulator whose inactivation has been found to be a key event in malignant transformation. Reconstitution of wild-type p53 in the p53-nonproducer, Abelson murine leukemia virus-transformed pre-B-cell line L12 gave rise to stably growing clones. Wild-type p53-producer derived cell lines exhibit an altered cell cycle, however. More cells with an extended G0/G1 phase were found than in the p53-nonproducer parental cell line. Furthermore, when injected into syngeneic mice, these cells induced a lower incidence of tumors and these tumors were less aggressive. Analysis of immunoglobulin expression revealed that wild-type p53 induced the expression of cytoplasmic immunoglobulin mu heavy chain. In addition, these derived cells lines exhibited increased levels of a B-cell-specific surface marker, B220. These results suggest that wild-type p53 may function as a cell differentiation factor that can induce development of pre-B cells into a more advanced stage in the pathway of B-cell maturation. In these pre-B cells, wild-type p53 may induce cell differentiation without terminal growth arrest of the cell population.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1924360      PMCID: PMC52635          DOI: 10.1073/pnas.88.20.8982

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.

Authors:  P Hinds; C Finlay; A J Levine
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

2.  The p53 proto-oncogene can act as a suppressor of transformation.

Authors:  C A Finlay; P W Hinds; A J Levine
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

3.  Monoclonal antibody analysis of p53 expression in normal and transformed cells.

Authors:  J W Yewdell; J V Gannon; D P Lane
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Meth A fibrosarcoma cells express two transforming mutant p53 species.

Authors:  D Eliyahu; N Goldfinger; O Pinhasi-Kimhi; G Shaulsky; Y Skurnik; N Arai; V Rotter; M Oren
Journal:  Oncogene       Date:  1988-09       Impact factor: 9.867

5.  Immunologically distinct p53 molecules generated by alternative splicing.

Authors:  N Arai; D Nomura; K Yokota; D Wolf; E Brill; O Shohat; V Rotter
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

6.  Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; S H Advani; S Benchimol; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Loss of a highly conserved domain on p53 as a result of gene deletion during Friend virus-induced erythroleukemia.

Authors:  D G Munroe; B Rovinski; A Bernstein; S Benchimol
Journal:  Oncogene       Date:  1988-06       Impact factor: 9.867

8.  B220: a B cell-specific member of th T200 glycoprotein family.

Authors:  R L Coffman; I L Weissman
Journal:  Nature       Date:  1981-02-19       Impact factor: 49.962

9.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

10.  A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus.

Authors:  N Rosenberg; D Baltimore
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

View more
  41 in total

1.  Circadian variation in the expression of cell-cycle proteins in human oral epithelium.

Authors:  G A Bjarnason; R C Jordan; R B Sothern
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

2.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

3.  p53-Dependent induction of PVT1 and miR-1204.

Authors:  Anthony M Barsotti; Rachel Beckerman; Oleg Laptenko; Konrad Huppi; Natasha J Caplen; Carol Prives
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

4.  The ups and downs of p53 regulation in hematopoietic stem cells.

Authors:  Hussein A Abbas; Vinod Pant; Guillermina Lozano
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

5.  Regulation of ES cell differentiation by functional and conformational modulation of p53.

Authors:  K Sabapathy; M Klemm; R Jaenisch; E F Wagner
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

6.  Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression.

Authors:  F J Ortega; J M Moreno-Navarrete; D Mayas; M Serino; J I Rodriguez-Hermosa; W Ricart; E Luche; R Burcelin; F J Tinahones; G Frühbeck; G Mingrone; J M Fernández-Real
Journal:  Int J Obes (Lond)       Date:  2013-09-03       Impact factor: 5.095

7.  Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses.

Authors:  D Ronen; Y Teitz; N Goldfinger; V Rotter
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

8.  Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation.

Authors:  Jian Huang; Keqiang Chen; Jiaqiang Huang; Wanghua Gong; Nancy M Dunlop; O M Zack Howard; Xiuwu Bian; Yuqi Gao; Ji Ming Wang
Journal:  Carcinogenesis       Date:  2008-11-26       Impact factor: 4.944

9.  Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.

Authors:  B Roy; J Beamon; E Balint; D Reisman
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.

Authors:  U M Moll; M LaQuaglia; J Bénard; G Riou
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.